MxEP与EP方案治疗晚期非小细胞肺癌的疗效比较

目的: 观察和比较MxEP与EP方案治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法: 30例Ⅲ~Ⅳ期NSCLC采用MxEP方案[足叶乙甙(VP16)75mg/m2,第1~5天;顺铂(DDP)30mg/m2,第1~3天;米托蒽醌(MxT)10mg,第2天]联合化疗。27例Ⅲ~Ⅳ期NSCLC采用EP方案(VP16 75mg/m2,第1~5天;DDP 30mg/m2,第1~3天)联合化疗。结果: MxEP组CR和PR共17例,有效率56.7%,中位缓解期6个月,中位生存期13个月;EP组CR和PR共11例,有效率33.3%,中位缓解期3个月,中位生存期8个月,两组疗效差异有显著性(Ρ<0.05)。主要的毒副反应为食欲减退、恶心呕吐、白细胞、血小板减少,患者均可耐受。结论: MxEP是治疗晚期非小细胞肺癌的一种可以选择的方案。

Comparison of MxEP and EP regimen in treatment for advanced non-small cell lung cancer

Objective: To observe and compare the effect and major adverse reaction of the two chemotherapy regimens(MxEP and EP) in treatment of advanced non-small cell lung cancer (NSCLC).Methods: Thirty cases of advanced NSCLC (stage Ⅲ-Ⅳ) patients were treated with MxEP regimen(MxT 10 mg,d₂;VP16 75 mg/m2,d_1-5;DDP 30 mg/m2,d_1-3),and the other 27 cases were treated with EP regimen (VP 16 75 mg/m2,d_1-5;DDP 30 mg/m2,d_1-3).Results: In the MxEP group,the overall response rate was 56.7%(CP+PR=17),the medium response time was 6 months and the medium survival time was 13 months.In the EP group,the overall response rate was 33.3%(CP+PR=11),the medium response time and medium survival time were 3 and 8 months.The major side effects were anorexia,nausea,vomiting,leucopenia and thrombocytopenia,which were tolerable for most cases.Conclusions: The MxEP regimen is a good choice for treatment of NSCLC.